Mattawan Brings Expanded Expertise

In April 2018, Charles River Laboratories completed the acquisition of MPI Research, a premier nonclinical contract research organization (CRO). The acquisition enhances Charles River’s position as a leading global early-stage CRO by strengthening our ability to partner with clients across the drug discovery and development continuum. MPI Research will continue under our Safety Assessment umbrella, providing critical services, new capabilities, and expanded capacity for the growing biotechnology industry.
 

Integration Update

Watch as our leaders discuss the positive impacts on our staff and operations, commercial successes, and the value our enhanced team brings to your programs. The addition of these experts and scientists from MPI Research brings fresh perspectives and years of experience to our growing Safety Assessment team. Read more about Mattawan

Scientific Spotlight | Ototoxicity Testing

Ototoxicity testing is only one of the specialty focus areas Charles River is excited to add to its portfolio stemming from the MPI Research acquisition. Watch as Senior Study Director of Ototoxicity Testing, Rachel Tapp, shares the extensive capabilities this area can offer and the growing trends within the industry. Learn more about our ototoxicity services

Scientific Spotlight | Cell & Gene Therapy

Development of new cell and gene therapy treatments is a trending topic within the industry and through the MPI Research acquisition, Charles River is enhancing its expertise and portfolio. Watch as our Senior Director of Surgery, Mark Johnson, and Director of Experimental Therapeutics, Tom Vihtelic, discuss scientific collaborations and the future of these innovative developing therapies. Learn more about our cell and gene therapy services

Accelerate your drug development program timelines with our expanded network of scientists. Reach out to our team to speak with an expert and to plan your next project. Start planning now